里昂发布研报称，维立志博-B（09887）上半年合作收入为3，600万元人民币，该行预期催化剂包括LBL-024用于一线非小细胞肺癌（NSCLC）的数据更新，将于本月举行的2026年世界肺癌大会（WCLC）上以口头报告形式发布。公司指引LBL-024用于一线NSCLC的III期临床试验将于2027年启动，并自上月起积极寻求全球合作伙伴。该行上调今年销售预测35.6%，并对2026至28年盈利预测作出调整（-15%、-25.7%及+14.6%），目标价由108港元上调至116.9港元，维持“跑赢大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.